Cash flow covers the payout many times over, but the rate has been flat for years and leverage sits in the review band. Viatris pays $0.12 a quarter, $0.48 annualized, unchanged since the raise from $0.11 in early 2023 — no cut, but flat for more than three years. Dividends of $591 million are 23% of 2025 free cash flow of $2,523 million, a pass. Two cautions grade it warn: the flat rate, and net debt of $13,055 million at 3.7x EBITDA of $3,507 million, in the review band. Earnings are near zero after large amortization and impairment charges, so the grade rests on cash flow, not EPS.
Key risk: Generic-drug pricing pressure and a heavy debt load mean deleveraging, not dividend growth, is the priority; the payout is safe on cash flow today but has no growth record behind it.
Changes if: The rate rises, or net debt/EBITDA falls below 3x, or free-cash-flow payout crosses 60%.
- ✓Cash-flow cover 23.4% of FY2025 free cash flow, pass (<60%).
- !Leverage 3.7x net debt/EBITDA, review band (3-4x), a caution.
- !Dividend history $0.12 flat since March 2023; flat 3+ years is the caution band. No cut.
- ✓Trap screen Yield 2.56%, payout under 100% on cash flow, no cut; not a trap pattern.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.